VPT:CC - Ventripoint's VMS+ Purchased by Medical Center - University of Freiburg
(TheNewswire)
Toronto, Ontario – The Newswire –July 18, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announce that Freiburg Hospitalhas chosen to adopt the VMS+ as its cardiac diagnostic tool.
The University Medical Centre Freiburg im Breisgau,Germany, is notably one of the largest hospitals in Europe and isrecognized as the supra-regional centre for the treatment ofcomplicated heart disease. It treats approximately 90,000 inpatients and897,000 outpatients annually.
Dr. Alvira Macanovic, Ventripoint’s President and CEOstated, “This year the Ventripointteam is laser-focused on sales growth and this sale to a leadinginstitution in Europe is indicative of the sales momentum and tractionwe are seeing in one of our key markets through the cooperativeefforts of our direct sales team, channel partners, and trial teams.
The VMS+ will be utilized by the department ofcongenital heart defects and paediatric cardiology who treat 4,000+children, youth, and young adults with congenital and acquired heartdiseases each year. With the VMS+, the cardiac medical centre will beable to make its diagnostic and procedural decisions more efficientlyand quickly, leading to better outcomes for patients. The VMS+ willserve as an adjunct to speed up decision-making in patient treatmentand as an alternative to cardiac MRI when a patient iscontraindicated. Most importantly, VMS+ will be used to aid indiagnosis and in continuous monitoring of patients throughout theirjourney as performing a VMS+ study fits normal scanning workflows. The VMS+ will also be used to assist in the research of terminalheart failure and mechanical cardiovascular replacement and inpediatric drug trials for congenital heart defects.
Sales, installation and support of the VMS+ in Europeis handled by Angiopro GmbH. The cooperation between Ventripoint andAngiopro ensures optimal customer service, so that all VMS+ users canrely on intensive and timely support.
Ventripoint is committed to elevating cardiac carethrough innovative products like the VMS+ and will continue to workwith healthcare professionals and institutions to develop solutionsthat improve the patient care journey.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Angiopro GmbH
Angiopro is aclassic distributor company with headquarters in Speyer,Rhineland-Palatinate. The company portfolio includes the distributionof vascular medical devices as well as the world's leading software inpatient screening before and after cardiovascular interventions.Website: www.angiopro.de
About Medical Center – Universityof Freiburg
With roughly 15,000 employees, the Medical Center –University of Freiburg is among the largest university medical centersin Germany. Around 1,800 doctors and more than 4,300nurses provide care to more than 90,000 inpatients andaround 900,000 outpatients per year.
The Medical Center – University of Freiburg engagesin research, teaching, and healthcare as its core responsibilities,always with the goal of offering its patients treatment informed bythe latest scientific findings – today and in the future.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placedon the forward-looking statements and information because the Companycan give no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.